<DOC>
	<DOCNO>NCT00002705</DOCNO>
	<brief_summary>Phase I trial study effectiveness topotecan treat child refractory leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Topotecan Treating Children With Refractory Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Describe qualitative quantitative toxic effect , include acute chronic dose-limiting toxicity , cumulative toxicity , time recovery , pediatric patient refractory leukemia treat 30-minute daily infusion topotecan ( TOPO ) 12 consecutive day every 3 week . II . Estimate maximum tolerate dose TOPO result tolerable , predictable , reversible toxicity . III . Determine precaution supportive therapy use clinical laboratory study need monitor alter therapy prevent unacceptable toxicity patient . IV . Observe antileukemic effect may occur phase I study duration treatment increase 7 9 12 day TOPO dose escalate . V. Determine recommend phase II pediatric dose TOPO . VI . Characterize pharmacokinetic parameter TOPO evaluate change parameter first last dos determine whether drug accumulation . VII . Correlate , possible , pharmacokinetic parameter clinical response toxicity . OUTLINE : Single-Agent Chemotherapy . Topotecan , TOPO , NSC-609699 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm leukemia refractory conventional therapy effective curative therapy exist PATIENT CHARACTERISTICS : Age : Under 21 Performance status : ECOG 02 Life expectancy : At least 8 week Adequate platelet count hemoglobin require ( transfusion allow ) Bilirubin great 1.5 mg/dL AST ALT great 2 time normal Creatinine le 1.5 mg/dL Adequate nutritional status , e.g . high third percentile weight height Albumin least 3 g/dL No severe uncontrolled infection No pregnant woman Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : At least 3 week since systemic chemotherapy ( 6 week since nitrosoureas ) Recovered least 3 month since bone marrow transplant ( least 6 month since totalbody irradiation ) No concurrent anticancer therapy No concurrent treatment study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>